These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 9390784)

  • 1. Cerebrospinal fluid C3a increases with age, but does not increase further in Alzheimer's disease.
    Loeffler DA; Brickman CM; Juneau PL; Perry MF; Pomara N; Lewitt PA
    Neurobiol Aging; 1997; 18(5):555-7. PubMed ID: 9390784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intrathecal levels of complement-derived soluble membrane attack complex (sC5b-9) correlate with blood-brain barrier dysfunction in patients with traumatic brain injury.
    Stahel PF; Morganti-Kossmann MC; Perez D; Redaelli C; Gloor B; Trentz O; Kossmann T
    J Neurotrauma; 2001 Aug; 18(8):773-81. PubMed ID: 11526983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic analysis of the complement pathways in patients with neuromyelitis optica indicates alteration but no activation during remission.
    Veszeli N; Füst G; Csuka D; Trauninger A; Bors L; Rozsa C; Nagy Z; Jobbágy Z; Eizler K; Prohászka Z; Varga L; Illes Z
    Mol Immunol; 2014 Feb; 57(2):200-9. PubMed ID: 24172223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased soluble C5b-9 in CSF of neuromyelitis optica.
    Wang H; Wang K; Wang C; Qiu W; Lu Z; Hu X
    Scand J Immunol; 2014 Feb; 79(2):127-30. PubMed ID: 24313854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Preanalytical Procedures on Complement Biomarkers in Cerebrospinal Fluid and Plasma from Controls and Alzheimer's Disease Patients.
    Gutierrez J; Kurz C; Sandoval C; Edmonds R; Bittner T; Perneczky R; Biever A
    J Alzheimers Dis; 2024; 101(2):563-576. PubMed ID: 39213066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cisterno-lumbar gradient of complement fractions in geriatric patients with suspected normal pressure hydrocephalus.
    Seele J; Kirschfink M; Djukic M; Lange P; Gossner J; Bunkowski S; Wiltfang J; Nau R
    Clin Chim Acta; 2018 Nov; 486():1-7. PubMed ID: 30003878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in cerebrospinal fluid gangliosides between "probable Alzheimer's disease" and normal aging.
    Blennow K; Davidsson P; Wallin A; Fredman P; Gottfries CG; Månsson JE; Svennerholm L
    Aging (Milano); 1992 Dec; 4(4):301-6. PubMed ID: 1294245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activated complement components C3a and C4a in cerebrospinal fluid and plasma following subarachnoid hemorrhage.
    Kasuya H; Shimizu T
    J Neurosurg; 1989 Nov; 71(5 Pt 1):741-6. PubMed ID: 2809729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive value of complement activation fragments C3a and sC5b-9 for development of severe disease in patients with acute pancreatitis.
    Gloor B; Stahel PF; Müller CA; Schmidt OI; Büchler MW; Uhl W
    Scand J Gastroenterol; 2003 Oct; 38(10):1078-82. PubMed ID: 14621284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Formation of complement split products and proinflammatory cytokines by reinfusion of shed autologous blood.
    Bengtsson A; Avall A; Hyllner M; Bengtson JP
    Toxicol Lett; 1998 Nov; 100-101():129-33. PubMed ID: 10049132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SC5b-9 is the most sensitive marker in assessing disease activity in Brazilian SLE patients.
    Chiu YY; Nisihara RM; Würzner R; Kirschfink M; de Messias-Reason IJ
    J Investig Allergol Clin Immunol; 1998; 8(4):239-44. PubMed ID: 9777539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Usefulness of pleural complement activation products in differentiating tuberculosis and malignant effusions.
    Porcel JM; Vives M; Gázquez I; Vicente de Vera MC; Pérez B; Rubio M
    Int J Tuberc Lung Dis; 2000 Jan; 4(1):76-82. PubMed ID: 10654648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complement activation in cerebrospinal fluid in clinically isolated syndrome and early stages of relapsing remitting multiple sclerosis.
    Håkansson I; Ernerudh J; Vrethem M; Dahle C; Ekdahl KN
    J Neuroimmunol; 2020 Mar; 340():577147. PubMed ID: 31951875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pleural SC5b-9: a test for identifying complicated parapneumonic effusions.
    Vives M; Porcel JM; Gázquez I; Pérez B; Rubio M
    Respiration; 2000; 67(4):433-8. PubMed ID: 10940799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer's disease, and apolipoprotein E-epsilon4/4 genotype.
    Liu RY; Zhou JN; van Heerikhuize J; Hofman MA; Swaab DF
    J Clin Endocrinol Metab; 1999 Jan; 84(1):323-7. PubMed ID: 9920102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alterations in plasma complement levels after human ischemic stroke.
    Mocco J; Wilson DA; Komotar RJ; Sughrue ME; Coates K; Sacco RL; Elkind MS; Connolly ES
    Neurosurgery; 2006 Jul; 59(1):28-33; discussion 28-33. PubMed ID: 16823297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative pathway activation of the complement system in preterm infants with early onset infection.
    Zilow EP; Hauck W; Linderkamp O; Zilow G
    Pediatr Res; 1997 Mar; 41(3):334-9. PubMed ID: 9078531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CSF levels of the histamine metabolite tele-methylhistamine are only slightly decreased in Alzheimer's disease.
    Motawaj M; Peoc'h K; Callebert J; Arrang JM
    J Alzheimers Dis; 2010; 22(3):861-71. PubMed ID: 20858978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal fluid complement activation in patients with pneumococcal and meningococcal meningitis.
    Mook-Kanamori BB; Brouwer MC; Geldhoff M; Ende Av; van de Beek D
    J Infect; 2014 Jun; 68(6):542-7. PubMed ID: 24412248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Complement Factors With Disability Progression in Primary Progressive Multiple Sclerosis.
    Lunemann JD; Hegen H; Villar LM; Rejdak K; Sao-Aviles A; Carbonell-Mirabent P; Sastre-Garriga J; Mongay-Ochoa N; Berek K; Martínez-Yélamos S; Pérez-Miralles F; Abdelhak A; Bachhuber F; Tumani H; Lycke JN; Rosenstein I; Alvarez-Lafuente R; Castillo-Trivino T; Otaegui D; Llufriu S; Blanco Y; Sánchez López AJ; Garcia Merino JA; Fissolo N; Gutierrez L; Villacieros-Álvarez J; Monreal E; Valls-Carbó A; Wiendl H; Montalban X; Comabella M
    Neurol Neuroimmunol Neuroinflamm; 2024 Jul; 11(4):e200270. PubMed ID: 38912898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.